It’s been a difficult quarter for the biotech sector, with economies struggling to recover from high inflation making for a small appetite for risk. The ASX.
Immuron Ltd (NASDAQ:IMRN, ASX:IMC), an immunotherapy-focused biopharmaceutical company based in Australia, is readying to proceed with clinical evaluation.
Check Up: Immuron wins big in US and Europe on travellers diarrhoea drug stockhead.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockhead.com.au Daily Mail and Mail on Sunday newspapers.